Most Popular
Ten Deadly Sins of Rare Diseases
Exploring RHO-Related Pathogenic Mechanisms and RHO Gene Therapy Research Progress [Ten Deadly Sins of Rare DiseasesⅠ]
Jun 30, 2023
June 6th, 2023 is the 28th National Eye Care Day of China. Do you know the theme of this year's Eye Care Day? Read More >
Research Trends
What are the Best Transgenic Animal Models for Alzheimer's Disease Research?
Jun 20, 2023
When it comes to Alzheimer's disease (AD), people may think of various emotional scenes portrayed in movies and TV shows. However, the reality is much more cruel, as we can see from the trending topic“They Will Forget Love And They Will Forget You”. Read More >
Research Trends
Common Mouse Models for Preclinical Alzheimer's Disease Research
Jun 15, 2023
After being diagnosed with Alzheimer’s in his later years, the famous British fantasy author Terry Pratchett described the disease in his writings: “On the first day of my journalistic career I saw my first corpse… All I can say is that, compared with his horrific demise, Alzheimer's is a walk in the park. Except with Alzheimer's my park keeps changing. The trees get up and walk over there, the benches go missing and the paths seem to be unwinding into particularly vindictive serpents.”. Read More >
Breaking News
YIMA and ZIP Solutions Announce Strategic Co-Marketing Agreement for Gene Therapy
Jun 08, 2023
ZIP Solutions (Barcelona), a 100% affiliate of Biat Group (ticker BST), and YIMA Gene, a subsidiry under Cyagen Group, are please to announce a strategic co-marketing agreement for gene therapy. Read More >
Research Trends
How to overcome the challenge of model selection in DMD gene therapy?
May 30, 2023
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder caused by mutations in the DMD gene, resulting in abnormal function of the dystrophin protein. Read More >
Research Trends
Advancements in CAR-T Cell Therapy: Maximizing Therapeutic Efficacy while Minimizing Toxicity
May 26, 2023
In the last chapter (click to review), we mentioned that chimeric antigen receptor (CAR)-T cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies expressing CD19, however, there are still many toxicities in clinical applications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Read More >
Research Trends
What are the obstacles hindering the development of CAR-T therapy?
May 18, 2023
After years of development, chimeric antigen receptor (CAR) T cell therapy has become a revolutionary method for cancer treatment. Among them, CD19 targeting drugs have achieved unprecedented success in the treatment of B-cell malignancies and were approved by the US FDA in 2017. Read More >
Research Trends
Mastering CAR Structure and Design for Enhanced Anti-Tumor Response with CAR-T Cell Therapy
May 12, 2023
Chimeric antigen receptors (CARs) are engineered synthetic receptors that redirect lymphocytes, most commonly T-cells, to recognize and eliminate cells expressing specific target antigens. CAR binding to target antigens on the cell surface is independent of MHC receptors, resulting in vigorous T-cell activation and potent anti-tumor responses. Read More >
Newsletter
Cyagen CEO Lance Han - Pushing Therapeutic Advances Through Modelling
Apr 24, 2023
Cyagen Biosciences CEO Lance Han was recently featured in an interview with CEO Insights Asia Magazine. In the interview, Han discussed his vision for the future of biotech and gene editing and shared insights on how Cyagen is pioneering innovation in cell and gene therapy research through data-driven solutions. Additionally, Han was recognized by the magazine as one of the TOP 10 TSINGHUA UNIVERSITY ALUMNI LEADERS - 2023, a prestigious accolade that showcases his exceptional leadership skills and contributions to the biotech industry. Read More >
Research Trends
Frequently Asked Questions (FAQ) on Mouse Models for Ophthalmic Diseases
Apr 21, 2023
Due to the limited efficacy of traditional treatments, ophthalmic diseases have quickly become a breakthrough point for gene therapy, but many questions about mouse models for preclinical ophthalmology research remain. Read More >